3S Corporation

Established in 1999 by Omprakash Mantry, 3S Corporation is a prominent pharmaceutical exporter based in Mumbai, Maharashtra, India. The company specializes in the export and wholesale distribution of a diverse range of pharmaceutical products, including oncology, critical care, diabetes, and heart care medications. Additionally, 3S Corporation deals in antiretroviral drugs, orphan drugs, over-the-counter medications, and vaccines. Operating as a government-recognized export house, the company sources and delivers authentic drugs from over 40 countries, exporting to more than 180 nations worldwide.

The company's registered office is located at A/14 Bonanza Industrial Estate, Ashok Chakravarty Road, Kandivali (East), Mumbai, Maharashtra, 400101, India. 3S Corporation is a privately held entity, with ownership details not publicly disclosed. The company operates under the Corporate Identification Number (CIN) U51909MH2021PTC370327, as per the Ministry of Corporate Affairs, Government of India. While specific revenue figures are not publicly available, the company has demonstrated consistent growth and expansion in its export operations. The workforce comprises approximately 25 full-time employees, many of whom have been with the company for over a decade, reflecting a stable and experienced team.

3S Corporation operates a centralized warehouse and storage facility in Mumbai, Maharashtra. The facility spans a combined office space of 4,200 square feet and includes multi-temperature storage capabilities to ensure the integrity of pharmaceutical products. The storage areas consist of an ambient room maintained at 15°–25°C and two state-of-the-art cold rooms operating at 2°–8°C, with capacities of 260 and 505 cubic feet, respectively. These cold rooms are equipped with constant temperature monitoring and alarm systems to detect any temperature excursions or refrigeration failures, ensuring compliance with global standards for the storage and distribution of pharmaceutical products.

The leadership team at 3S Corporation is headed by Managing Director Piyansh Omprakash Mantry, who has been associated with the company since its inception. Under his guidance, the company has expanded its product range and global reach. Other key executives include Omprakash Shankarlal Mantry, serving as Director, and Bela Desai, who heads the Accounts & Finance department. The marketing team is led by Senior Marketing Manager Jisha Sukumaran and Marketing Manager for Africa & South American Region, Larissa Dsilva. The purchase department is managed by Niwas Jhawar, ensuring efficient procurement processes.

3S Corporation's export activities are primarily focused on regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company adheres to the regulatory requirements of these regions, ensuring that all exported pharmaceutical products meet the necessary standards for quality and safety. While specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed, 3S Corporation's compliance with global standards and its WHO-GSDP (Good Storage and Distribution Practices) accreditation indicate a commitment to maintaining high-quality standards in its export operations.

In addition to established markets, 3S Corporation has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's ability to source and deliver authentic pharmaceutical products from over 40 countries has facilitated its expansion into these regions. The WHO-GSDP accreditation further enhances the company's credibility and ability to meet the regulatory requirements of these emerging markets, enabling access to a broader customer base.

3S Corporation's geographic strategy demonstrates a strong diversification approach, with exports spanning over 180 countries worldwide. This extensive reach mitigates concentration risk and positions the company to leverage growth opportunities across various regions. The strategic focus on sourcing products from over 40 countries and exporting to a diverse set of markets reflects a well-balanced and forward-looking approach to global expansion.

Specific details regarding 3S Corporation's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to global standards and its WHO-GSDP accreditation suggest a commitment to maintaining high-quality standards in its export operations. The absence of publicly available FDA-related information indicates that 3S Corporation may not currently hold FDA approvals for its products.

3S Corporation holds a WHO-GSDP (Good Storage and Distribution Practices) accreditation, indicating compliance with the World Health Organization's standards for the storage and distribution of pharmaceutical products. This accreditation underscores the company's commitment to maintaining high-quality standards in its export operations. Specific details regarding EU Good Manufacturing Practice (GMP) certificates and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The absence of publicly available information suggests that 3S Corporation may not currently hold EU GMP certifications or EDQM status.

3S Corporation operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses issued by the Maharashtra Food and Drug Administration (FDA), with license numbers 20-B/MZ6-23015 and 21-B/MZ6-23016. These licenses authorize the company to manufacture and distribute pharmaceutical products within India. The company's compliance with CDSCO regulations and state drug controller approvals ensures adherence to national standards for pharmaceutical manufacturing and distribution.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to 3S Corporation by regulatory authorities. The absence of such records suggests that the company maintains a clean regulatory history, reflecting its commitment to compliance with industry standards and regulations. However, the lack of publicly available information regarding FDA approvals and certifications indicates that 3S Corporation may not currently hold approvals for its products in certain regulated markets.

3S Corporation operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, the company's focus on oncology, critical care, diabetes, and heart care medications positions it in direct competition with other exporters specializing in these therapeutic areas. The company's ability to source and deliver authentic pharmaceutical products from over 40 countries and export to more than 180 nations worldwide enhances its competitive edge. Additionally, the WHO-GSDP accreditation and compliance with global standards for storage and distribution further strengthen its position in the market.

3S Corporation's key differentiators include its extensive network of manufacturers, dealers, wholesalers, and retailers across India, enabling the sourcing of a wide range of pharmaceutical products. The company's specialization in supplying bulk quantities of difficult-to-find drugs and medicines at competitive rates caters to a niche market segment. The focus on branded quality products and the guarantee of 100% genuine and authentic drugs enhance the company's reputation and trustworthiness among clients. The WHO-GSDP accreditation underscores the company's commitment to maintaining high-quality standards in the storage and distribution of pharmaceutical products.

3S Corporation's current strategic direction focuses on the export and wholesale distribution of a diverse range of pharmaceutical products, with a particular emphasis on oncology and life-saving drugs. The company's expansion into various therapeutic areas, including critical care, diabetes, and heart care, reflects a strategic approach to diversifying its product portfolio. The commitment to sourcing authentic drugs from over 40 countries and exporting to more than 180 nations worldwide positions the company for sustained growth and global reach. The WHO-GSDP accreditation and adherence to global standards for storage and distribution further reinforce the company's strategic position in the pharmaceutical export sector.

3S Corporation has demonstrated a strong track record in the pharmaceutical export sector, with a total export value of $505,000 USD and 264 shipments across 13 products in four therapeutic categories. The company's portfolio concentration is notable, with the top five products accounting for 75.8% of total exports. The focus on high-demand products such as Cyclophosphamide, Warfarin, Procarbazine, Daunorubicin, and Mefloquine indicates a strategic approach to meeting market needs.